BeStock  
Stocks › Biotechnology › RPRX

Royalty Pharma RPRX

US equityMarket cap rank #641Biotechnology
$68.45 +$0.73 (+1.08%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $67.91 -0.79%
Open$68.17
Prev close$67.72
Day range$67.95 – $68.83
Volume3.53M
Market cap$30.48B
P/E (TTM)44.7
Dividend yield1.35%

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$690.10M+13.3% YoY
Operating profit$561.20M+31.4% YoY
Net profit$266.64M-39.4% YoY
Diluted EPS$0.32-51.5% YoY
Free cash flow$686.08M-2.4% YoY
Operating cash flow$686.08M

Revenue, last 8 quarters

$593.6MDec '24$568.2MMar '25$578.7MJun '25$609.3MSep '25$622.0MDec '25$630.6MMar '26$674.1MJun '26$690.1MSep '26

Net profit, last 8 quarters

$334.4MDec '24$434.4MMar '25$92.6MJun '25$440.2MSep '25$356.9MDec '25$468.3MMar '26$81.5MJun '26$266.6MSep '26

Diluted EPS by quarter

0.35Dec '240.55Mar '250.07Jun '250.66Sep '250.38Dec '250.67Mar '260.04Jun '260.32Sep '26

Free cash flow by quarter

$742.5MDec '24$596.1MMar '25$364.0MJun '25$702.6MSep '25$827.1MDec '25$718.2MMar '26$728.5MJun '26$686.1MSep '26

Annual revenue

$2.1BFY20$2.3BFY21$2.2BFY22$2.4BFY23$2.3BFY24$2.4BFY25

Profitability & balance sheet

Operating margin65.5%
Net margin25.7%
Return on equity10.1%
Return on assets3.5%
Return on invested capital6.6%
Current ratio1.29
Liabilities / assets49.7%
Cash & investments$1.48B
Total debt$8.59B
Net cash (debt)-$7.11B
Free cash flow / sales113.1%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Cystic fibrosis franchise$212.20M 30.7%
  • Other products$185.07M 26.8%
  • Tremfya$77.11M 11.2%
  • Evrysdi$59.37M 8.6%
  • Voranigo$44.91M 6.5%
  • Other royalty income and revenues$42.50M 6.2%
  • Trelegy$39.62M 5.7%
  • TYSABRI$29.34M 4.3%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $690.10M $674.14M $630.58M $2.38B $621.99M
Operating Expense $128.91M $541.02M -$1.91M $818.68M $233.61M
Selling and Admin Expenses $150.10M $161.89M $159.49M $573.48M $164.27M
-General & Admin Expense $150.10M $161.89M $159.49M $573.48M $164.27M
Research & Development $63.16M $97.85M $39.79M $452.00M $50.50M
Asset Impairment Loss $3.97M $13.07M -$3.70M $89.03M -$4.27M
Other Operating Expenses -$88.32M $268.22M -$197.49M -$295.84M $23.11M
Operating Profit $561.20M $133.12M $632.48M $1.56B $388.38M
Net Non-Operating Interest Income (Expense) -$85.15M -$88.49M -$87.49M -$274.07M -$87.10M
Non-Operating Interest Income $5.34M $5.13M $6.23M $33.59M $7.07M
Non-Operating Interest Expense $90.49M $93.62M $93.72M $307.66M $94.17M
Other Income (Expense) -$209.41M $36.86M -$76.73M $38.75M $55.63M
Gain on Sale of Security -$66.39M $34.28M -$26.85M $24.01M $59.80M
Earnings from Equity Interest $9.23M $4.08M $21.76M $29.09M $4.01M
Special Income (Charges) -$150.36M $0.00 -$69.44M – –
-Less:Write Off $150.36M $0.00 $69.44M – –
Other Non-Operating Income (Expenses) -$1.88M -$1.50M -$2.20M -$14.35M -$8.17M
Pretax Profit $266.64M $81.49M $468.26M $1.32B $356.91M
Tax $0.00 $0.00 $0.00 $0.00 $0.00
Net Profit $266.64M $81.49M $468.26M $1.32B $356.91M
Profit from Continuing Operations $266.64M $81.49M $468.26M $1.32B $356.91M
Minority Interests $121.96M $63.60M $173.57M $553.25M $141.71M
Net Income to Parent Company $144.68M $17.88M $294.69M $770.95M $215.21M
Net Income to Common Stockholders $144.68M $17.88M $294.69M $770.95M $215.21M
Basic EPS $0.32 $0.04 $0.67 $1.79 $0.50
Diluted EPS $0.32 $0.04 $0.67 $1.78 $0.38
Dividend Per Share $0.24 $0.24 $0.24 $0.88 $0.22
Total Revenue as Reported – $674.14M – $2.38B $621.99M

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $19.46B $19.82B $19.82B $19.62B $19.62B
Total Current Assets $1.53B $1.76B $1.43B $1.53B $1.53B
Cash and Cash Equivalents & Short-Term Investments $1.48B $1.73B $1.39B $1.49B $1.49B
-Cash and Cash Equivalents $513.66M $811.99M $586.40M $618.70M $618.70M
-Short Term Investments $968.08M $914.45M $801.74M $873.19M $873.19M
Receivables $35.93M $31.47M $27.51M $29.32M $29.32M
-Other Receivables $35.93M $31.47M $27.51M $29.32M $29.32M
Other Current Assets $7.90M $6.66M $10.16M $6.89M $6.89M
Total Non-Current Assets $17.94B $18.06B $18.39B $18.09B $18.09B
Investments and Advances $16.95B $17.07B $17.39B $17.09B $17.09B
-Available for Sale Securities $16.69B $16.81B $17.12B $16.80B $16.80B
-Long Term Equity Investment $262.34M $261.97M $265.70M $289.97M $289.97M
Goodwill and Other Intangible Assets $923.54M $923.54M $924.63M $924.63M $924.63M
-Goodwill $923.54M $923.54M $924.63M $924.63M $924.63M
Other Non-Current Assets $61.57M $62.96M $76.85M $79.29M $79.29M
Total Liabilities $9.67B $10.03B $9.88B $9.91B $9.91B
Total Current Liabilities $1.18B $630.93M $535.68M $636.21M $636.21M
Payables $102.48M $126.85M $112.90M $92.23M $92.23M
-Accounts Payable $31.42M $35.57M $25.48M $19.40M $19.40M
-Dividends Payable $71.06M $91.28M $87.42M $72.83M $72.83M
Current Accrued Expenses $19.69M $107.77M $25.30M $110.82M $110.82M
Short-Term Debt and Capital Lease Obligation $996.97M $380.00M $380.00M $380.00M $380.00M
-Current Debt $996.97M $380.00M $380.00M $380.00M $380.00M
Other Current Liabilities $59.86M $16.32M $17.48M $53.16M $53.16M
Total Non-Current Liabilities $8.49B $9.40B $9.34B $9.27B $9.27B
Long Term Debt and Capital Lease Obligation $7.59B $8.58B $8.58B $8.57B $8.57B
-Long Term Debt $7.59B $8.58B $8.58B $8.57B $8.57B
Employee Benefits $774.45M $713.22M $648.67M $577.87M $577.87M
Other Non-Current Liabilities $121.98M $108.02M $117.79M $120.84M $120.84M
Total Equity $9.80B $9.79B $9.94B $9.71B $9.71B
Stockholders' Equity $6.84B $6.83B $6.89B $6.48B $6.48B
Capital Stock $108,000.00 $108,000.00 $108,000.00 $106,000.00 $106,000.00
-Common Stock $108,000.00 $108,000.00 $108,000.00 $106,000.00 $106,000.00
Additional Paid-In Capital $4.34B $4.38B $4.38B $4.12B $4.12B
Retained Earnings $2.50B $2.46B $2.51B $2.36B $2.36B
Less: Treasury Stock -$2.73M -$2.72M -$2.71M -$2.61M -$2.61M
Minority Interests $2.96B $2.95B $3.05B $3.24B $3.24B

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $686.08M $728.46M $718.23M $2.49B $827.15M
Net cash flow from continuing operations $686.08M $728.46M $718.23M $2.49B $827.15M
Net Income from Continuing Operations $266.64M $81.49M $468.26M $1.32B $356.91M
Gain/Loss from Continuing Operations -$590.45M -$669.70M -$596.58M -$2.31B -$656.23M
Depreciation & Depletion & Amortization $1.22M $1.29M $1.17M $3.85M $1.20M
Other Non-Cash Items $941.03M $826.00M $925.16M $3.40B $932.16M
Change in Working Capital -$111.14M $86.69M -$80.42M -$17.15M $48.51M
-Change in Receivables -$4.46M -$3.96M $1.81M -$2.36M -$415,000.00
-Change in Payables and Accrued Expense -$95.56M $90.60M -$90.60M -$4.99M $53.24M
-Change in Other Current Assets -$3.71M $1.01M -$4.91M -$7.45M -$3.31M
-Change in Other Current Liabilities -$7.41M -$954,000.00 $13.28M -$2.35M -$1.01M
Net cash flow from investing -$285.66M -$229.72M -$477.87M -$1.61B -$847.80M
Net Cash Flow from Continuing Investing Activities -$285.66M -$229.72M -$477.87M -$1.61B -$847.80M
Net Business Purchase and Sale $0.00 – – -$74.42M $0.00
Net Investment Purchase and Sale -$273.24M -$216.19M -$470.17M -$1.36B -$850.08M
Net Other Investing Changes -$13.41M -$317,000.00 -$50.00M -$280.26M -$2.71M
Financing Cash Flow -$698.74M -$273.15M -$272.67M -$1.19B -$299.60M
Net Cash Flow from Continuing Financing Activities -$698.74M -$273.15M -$272.67M -$1.19B -$299.60M
Net Common Stock Issuance -$86.34M -$44.64M -$50.10M -$1.23B -$80.54M
Cash Dividends Paid -$105.12M -$104.92M -$104.49M -$378.25M -$94.34M
Net Other Financing Charges -$127.29M -$123.59M -$118.08M -$534.81M -$124.72M
Ending Cash Balance $513.66M $811.99M $586.40M $618.70M $618.70M
Net Change in Cash -$298.33M $225.59M -$32.30M -$310.33M -$320.25M
Beginning Cash Balance $811.99M $586.40M $618.70M $929.03M $938.94M
Free Cash Flow $686.08M $728.46M $718.23M $2.49B $827.15M
Net Issuance Payments Of Debt – – – $954.48M $0.00

Discussion

No comments yet — be the first to weigh in on RPRX.

Sign in to join the discussion.

Scroll to Top